This page collects WhisperX intelligence signals tagged #Biotech Financing. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
GeoVax Labs, Inc. has filed a significant 8-K form with the SEC, disclosing a material definitive agreement and an unregistered sale of equity securities. The filing, submitted on March 31, 2026, indicates a pivotal corporate action that could reshape the company's financial and operational trajectory. The combination ...
Lobe Sciences has initiated a significant capital raise, announcing a non-brokered private placement of 14.62 million common shares priced at $0.065 each. The offering aims to generate gross proceeds of approximately $950,000, a move that places immediate focus on the company's cash position and strategic funding needs...
CERO Therapeutics Holdings, Inc. has filed a new 8-K with the SEC, disclosing a series of significant corporate actions that signal a major financial and operational shift. The filing, submitted on April 14, 2026, reveals the company has entered into a material definitive agreement, created a direct financial obligatio...
Vaxart, Inc. has filed a significant 8-K form with the SEC, signaling multiple material corporate developments. The filing, submitted on April 17, 2026, includes disclosures under four key items: the entry into a material definitive agreement, unregistered sales of equity securities, a Regulation FD disclosure, and the...
Calidi Biotherapeutics, Inc. has triggered multiple disclosure items in a new SEC 8-K filing that points to significant corporate activity. The biotech company reported both the entry into a material definitive agreement under Item 1.01 and unregistered sales of equity securities under Item 3.02, a combination that typ...